Despite the fact that great progress has been made in the development of therapies and predictive markers, like hormone receptor status, human epidermal growth factor receptor 2(Her-2) expression, and breast invasive carcinoma (BC) mutation status, there is insufficient knowledge on the understanding of the complicated pathophysiology of BC. Here, ERBB2 is linked to breast cancer.